Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

Publisher: John Wiley & Sons Inc

E-ISSN: 1097-0142|119|20|3653-3661

ISSN: 0008-543x

Source: CANCER, Vol.119, Iss.20, 2013-10, pp. : 3653-3661

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract